New Two-Target antibody for eczema tested in early trial
NCT ID NCT05859724
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either the drug or a placebo. The main goal was to check safety and how the drug moves through the body. The trial was terminated, so full results may not be available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NM26-2198 (a bispecific antibody targeting IL-4R and IL-31)
What this could lead to
If successful, this could point toward a new treatment option for moderate-to-severe atopic dermatitis that targets two inflammatory pathways at once.
What could go wrong
This was a very early (Phase 1) study focused on safety and dosing, not yet on effectiveness. The trial was terminated, so results may be limited or inconclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
COPERNICUS Podmiot Leczniczy Sp. z o.o., Szpital Sw. Wojciecha
Gdansk, 80-462, Poland
-
California Clinical Trials Medical Group (CCTMG) managed by Parexel
Glendale, California, 91206, United States
-
Centre de Recherche Saint-Louis
Québec, G1W4R4, Canada
-
D&H Tamarac Research Center
Tamarac, Florida, 33321, United States
-
DermEffects
London, Ontario, N6H5L5, Canada
-
First OC Dermatology Research
Fountain Valley, California, 92708, United States
-
Klinika Ambroziak Dermatologia
Warsaw, 02-953, Poland
-
Paddington Testing Co.
Philadelphia, Pennsylvania, 19103, United States
-
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych
Warsaw, 02-507, Poland
-
Sadick Research Group
New York, New York, 10075, United States
-
TCR Medical Corporation
San Diego, California, 92123, United States
-
UK-SH - Lübeck
Lübeck, Schleswig-Holstein, 23538, Germany
-
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, 01307, Germany
-
Universitätsmedizin Mainz
Mainz, Hesse, 55131, Germany
-
Uniwersytecki Szpital Kliniczny im. F.Chopina w Rzeszowie
Rzeszów, 35-055, Poland